Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase

Pharming Group (NASDAQ:PHAR) shares saw unusually-high trading volume on Wednesday . Approximately 6,830 shares changed hands during trading, an increase of 52% from the previous session’s volume of 4,496 shares.The stock last traded at $7.70 and had previously closed at $7.60.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, August 1st.

Pharming Group Stock Up 1.3 %

The business’s 50-day moving average is $7.84 and its 200-day moving average is $8.93. The company has a market capitalization of $518.55 million, a price-to-earnings ratio of -48.13 and a beta of 0.14. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The business had revenue of $74.09 million during the quarter, compared to analyst estimates of $71.95 million. During the same period in the previous year, the company posted $0.02 EPS. As a group, equities analysts predict that Pharming Group will post -0.15 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the SEC. 0.03% of the stock is owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.